https://www.austinchronicle.com/columns/2002-01-11/84311/
Even so, resistance tests should always inform treatment decisions, given the $1000-plus monthly cost of HIV drugs and the suffering caused by ineffective treatment.
Recently, however, the FDA approved Visible Genetics' Trugene, the first test to identify resistance-causing mutations quickly. A blood sample is sent to one of 130 Trugene-trained affiliate labs, where the viral genome is computer-decoded. All mutations are identified and matched to more than 70 mutations currently known to cause resistance to specific AIDS drugs. A year of FDA review found Trugene to be 98% accurate, and newly discovered mutation data can be quickly added to the computer software to keep Trugene current.
Especially because Trugene takes only three days and is competitive at $300-$500, this remarkable genetic testing process can be an important tool in helping physicians choose the most effective treatment combination for each patient, saving lives and money at the same time.
Copyright © 2025 Austin Chronicle Corporation. All rights reserved.